Enveric Biosciences, Inc. (ENVB)
1.42
-0.04
(-2.74%)
USD |
NASDAQ |
Sep 11, 16:00
1.445
+0.02
(+1.76%)
After-Hours: 20:00
Enveric Biosciences Enterprise Value : -2.707M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | -2.707M |
| September 10, 2026 | -2.550M |
| September 09, 2026 | -2.570M |
| September 08, 2026 | -2.707M |
| September 04, 2026 | -2.825M |
| September 03, 2026 | -2.629M |
| September 02, 2026 | -2.629M |
| September 01, 2026 | -2.904M |
| August 31, 2026 | -2.904M |
| August 28, 2026 | -2.904M |
| August 27, 2026 | -2.904M |
| August 26, 2026 | -2.904M |
| August 25, 2026 | -2.550M |
| August 24, 2026 | -2.747M |
| August 21, 2026 | -2.668M |
| August 20, 2026 | -2.825M |
| August 19, 2026 | -3.140M |
| August 18, 2026 | -2.983M |
| August 17, 2026 | -2.471M |
| August 14, 2026 | -2.255M |
| August 13, 2026 | -2.353M |
| August 12, 2026 | -2.196M |
| August 11, 2026 | -2.196M |
| August 10, 2026 | -2.235M |
| August 07, 2026 | -2.196M |
| Date | Value |
|---|---|
| August 06, 2026 | -2.156M |
| August 05, 2026 | -1.723M |
| August 04, 2026 | -1.645M |
| August 03, 2026 | -1.999M |
| July 31, 2026 | -2.117M |
| July 30, 2026 | -2.668M |
| July 29, 2026 | -3.062M |
| July 28, 2026 | -3.062M |
| July 27, 2026 | -3.022M |
| July 24, 2026 | -3.219M |
| July 23, 2026 | -3.101M |
| July 22, 2026 | -3.022M |
| July 21, 2026 | -3.101M |
| July 20, 2026 | -3.298M |
| July 17, 2026 | -3.022M |
| July 16, 2026 | -2.944M |
| July 15, 2026 | -3.101M |
| July 14, 2026 | -3.101M |
| July 13, 2026 | -3.140M |
| July 10, 2026 | -2.983M |
| July 09, 2026 | -2.668M |
| July 08, 2026 | -2.707M |
| July 07, 2026 | -2.589M |
| July 06, 2026 | -2.471M |
| July 02, 2026 | -2.589M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| LENZ Therapeutics, Inc. | -77.43M |
| Impact BioMedical, Inc. | 52.86M |
| ANI Pharmaceuticals, Inc. | 1.847B |
| Corcept Therapeutics, Inc. | 11.87B |
| Veru, Inc. | 18.49M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.028M |
| Total Expenses (Quarterly) | 3.028M |
| EPS Diluted (Quarterly) | -0.7594 |
| Earnings Yield | -1.16K% |
| Normalized Earnings Yield | -1159.15 |